Jul 8, 2025 · ↪ Click here to view our IAS roadmap IAS 2025, the 13th International AIDS Society (IAS) Conference on HIV Science will be held next week, July 13 – 17 in Kigali, Rwanda. IAS …

Jun 18, 2025 · AVAC’s The Gears of Lenacapavir for PrEP Rollout outlines the steps needed from national governments, funders, researchers, drug-makers including generic manufacturers, …

Jun 17, 2025 · ↪ Click for IAS 2025 resources and for our updates from the conference The IAS 2025 conference in Kigali will go down as a critical turning point in the history of the HIV …

AVAC is an international non-profit organization that leverages its independent voice and global partnerships to accelerate ethical development and equitable delivery of effective HIV …

Oct 1, 2018 · Our database allows users to view planned, ongoing, and completed clinical trials around the world, gaining an understanding of the many developments currently being made …

Jul 8, 2024 · Today a global cadre of HIV prevention advocates is calling for an accelerated timeline for access to the HIV prevention drug lenacapavir. Gilead, the developer of the drug, …

Aug 7, 2025 · The STI & HIV World Congress brought together over 1,400 researchers, healthcare providers, implementers, advocates, funders and industry representatives in …

AVAC Calls for Accelerated Regulatory Review and Ambitious Introduction Plans Contact: Kay Marshall +1 (347) 249-6375, [email protected] New York City, June 20, 2024 – AVAC …

Sep 12, 2024 · AVAC welcomes the groundbreaking results of the PURPOSE 2 HIV prevention study of twice-yearly injectable lenacapavir for PrEP among 3,200 cisgender men, transgender …

Read AVAC’s statement welcoming Gilead Sciences’ announcement in granting multiple, non-exclusive licenses to generic manufacturers to produce lenacapavir, their investigational twice …